title: Canakinumab in pediatric rheumatic diseases.
abstract: BACKGROUND
  Hitherto, some of the most severe forms of arthritis with onset in the neonatal period and early childhood have been resistant to conventional and anti-tumour necrosis factor agents. Recent results from drug trials of novel monoclonal antibodies will significantly alter the treatment of two of these diseases. This review is for canakinumab, a new monoclonal antibody to interleukin 1β that has been shown to be specifically efficacious in two groups of arthritis with systemic features.
  
  
  METHODS
  The clinical features and treatment to-date in the autoinflammatory disease, cryopyrin associated periodic fever syndrome and systemic juvenile idiopathic arthritis are briefly reviewed. An overview of current IL-1 inhibitors is provided. Clinical trials of Canakinumab in the treatment of these two diseases are evaluated.
  
  
  CONCLUSIONS
  The last decade has seen a major advance in treatment leading to remission while on therapy for many children with CAPS and sJIA. The outcomes of the anti-IL-1β and the anti-IL-6 trials for sJIA are quite similar and do not enable preferential use of either biological in a given patient.
authors: University medical Center Utrecht, Department Pediatric Rheumatology, Utrecht, Netherlands. N.wulffraat@umcutrecht.nl
authors: Nico M
authors: NM
authors: Wulffraat
authors: Patricia
authors: P
authors: Woo
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D002648:Child; D002986:Clinical Trials as Topic / Q000379:methods; D056587:Cryopyrin-Associated Periodic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000276:immunology; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053583:Interleukin-1beta; C541220:canakinumab